公开(公告)号：WO2023086341A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/049314

申请日：2022-11-08

Applicant: BIOMEA FUSION, INC.

Inventor： KIRSCHBERG, Thorsten A. ,  UNGASHE, Solomon B. ,  PHAN, Thu ,  SU, Yongli ,  WANG, Xiaodong ,  PALMER, James T. ,  BUTLER, Thomas ,  UPASANI, Ravindra B. ,  LIN, Nan-Horng ,  SPERANDIO, David ,  SQUIRES, Neil Howard ,  ADAM, Amna Trinity-Turjuman

IPC: C07D498/18 ,  C07D487/22 ,  C07D513/22 ,  A61P35/00 ,  A61K31/439 ,  A61K31/504

Abstract: Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.

公开(公告)号：WO2023001141A1

公开(公告)日：2023-01-26

申请号：PCT/CN2022/106447

申请日：2022-07-19

Applicant: SHANGHAI ZION PHARMA CO. LIMITED

Inventor： ZHOU, Ding ,  WANG, Zheng ,  CHENG, Ziqiang ,  CHEN, Shuai

IPC: C07D498/14 ,  C07D498/16 ,  C07D498/22 ,  C07D487/16 ,  C07D487/22 ,  C07D513/16 ,  C07D513/22 ,  A61P35/00 ,  A61K31/55 ,  A61K31/553 ,  A61K31/519 ,  A61K31/554 ,  A61K31/551 ,  A61K31/5513

Abstract: Provided novel compounds useful as KRAS G12D inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

公开(公告)号：WO2022246462A1

公开(公告)日：2022-11-24

申请号：PCT/US2022/072462

申请日：2022-05-20

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION ,  WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： KENT, Kenneth Craig ,  GUO, Lian-Wang ,  SHIRASU, Takuro ,  WANG, Bowen ,  GONG, Shaoqin ,  YODSANIT, Nisakorn

IPC: A61K49/00 ,  C07D487/22

Abstract: In one aspect, the disclosure relates to unimolecular micelles having N-hydroxysuccinimide ester (NHS), sulfo-NHS terminal groups, or other adhesive terminal groups, compositions including the same, methods of making the same, and methods of treating intimal hyperplasia in a subject using the same. In some aspects, the unimolecular micelles can further include fluorescent labels or drugs for treating intimal hyperplasia. In one aspect, the unimolecular micelles and compositions comprising the same are biocompatible, non-toxic, and non-inflammatory. In another aspect, the unimolecular micelles and compositions are substantially free from hydrogel, or are completely free from hydrogel. In still another aspect, the disclosed compositions and methods can be easily and quickly deployed in the operating room. Also disclosed is a method of applying the unimolecular micelles and compositions via direct penbrush painting.

公开(公告)号：WO2022216927A1

公开(公告)日：2022-10-13

申请号：PCT/US2022/023827

申请日：2022-04-07

Applicant: NORTH CAROLINA STATE UNIVERSITY ,  NIRVANA SCIENCES

Inventor： LINDSEY, Jonathan S. ,  MACNEVIN, Christopher ,  AKHIGBE, Joshua ,  GORCZYNSKI, Michael ,  TANIGUCHI, Masahiko

IPC: A61K49/00 ,  C07D487/22

Abstract: Described herein are compounds that include a first porphyrin; and a first hydroporphyrin, wherein the first porphyrin is attached to the first hydroporphyrin. The compound may be a luminescent compound (e.g., a fluorescent compound). Also provided are particles and compositions including compounds described herein. Further provided are methods of making and using the particles and methods of making the same.

公开(公告)号：WO2022174494A1

公开(公告)日：2022-08-25

申请号：PCT/CN2021/083440

申请日：2021-03-26

Applicant: 苏州科技大学

Inventor： 王筱梅 ,  居晓雷 ,  叶常青 ,  李琳 ,  朱琳

IPC: C07D487/22 ,  C07C15/28 ,  C09K11/07 ,  C09K11/06

Abstract: 本发明公开了多通道可调谐弱光上转换发光体系及其应用，其中弱光上转换双组份体系由八乙基卟啉钯、蒽衍生物与溶剂组成；弱光上转换单组份体系由八乙基卟啉钯与溶剂组成。利用红光照射弱光上转换双组份体系或者弱光上转换单组份体系，得到黄光或者蓝光，实现红光上转换。本发明的创造性在于首次公开了八乙基卟啉钯体系实现红光激发上转换材料，克服了现有技术认为八乙基卟啉钯都是绿光激发上转换材料的技术偏见。

公开(公告)号：WO2022166741A1

公开(公告)日：2022-08-11

申请号：PCT/CN2022/074255

申请日：2022-01-27

Applicant: 正大天晴药业集团股份有限公司

Inventor： 刘飞 ,  彭岩 ,  徐宏江 ,  任成 ,  严正磊

IPC: A61K31/439 ,  C07D498/22 ,  C07D487/22 ,  A61P35/00

Abstract: 一种含有苯并杂环的作为EGFR激酶抑制剂的大环化合物，具体公开了式I所示化合物或其药学上可接受的盐、立体异构体、互变异构体，其制备方法，含有该化合物的药物组合物，及其医药用途。

公开(公告)号：WO2022163377A1

公开(公告)日：2022-08-04

申请号：PCT/JP2022/001035

申请日：2022-01-14

Applicant: サンアプロ株式会社

Inventor： 白石　篤志 ,  川上　双葉

IPC: C07F5/00 ,  C07F5/06 ,  C09K3/00 ,  C07F7/02 ,  C07F7/30 ,  C07D487/22 ,  A61K47/68 ,  C07F9/6584 ,  A61K41/00

Abstract: 特定の構造を有する光増感剤であって、上記のように光照射によって親水性から疎水性へ急激な変化をもたらす場合において、従来よりも高感度な光増感剤を提供する。本発明は、ピロール環が直接又はπ共役により繋がった環構造を形成した環状配位子を有し、かつオニウム塩構造を有してなる軸配位子を有する、一般式（１）又は一般式（２）で表される金属錯体を含有する光増感剤；該光増感剤が結合してなる抗体結合体；５００～１５００ｎｍの光照射により軸配位子の脱離を促進させることを特徴とする該光増感剤の使用方法；該光増感剤を治療目的で使用する、使用方法である。

公开(公告)号：WO2022153294A1

公开(公告)日：2022-07-21

申请号：PCT/IL2022/050037

申请日：2022-01-11

Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD

Inventor： GROSS, Zeev ,  MAHAMMED, Atif

IPC: C07D487/22 ,  A61K31/407 ,  B01J31/22

Abstract: Embodiments of the invention relate to a corrole according to formula [I]; wherein R1, R2, and R3 are each independently H, -COOH, CF3, or a halide selected from the group consisting of F-, C1-, Br- and I, with the proviso that R1, R2, and R3 can not all be CF3, and when the compound is of Formula II, wherein M is a metallic ion or an elemental ion selected from the group consisting of an elemental ion of group 13-16 in row 3 or above and boron, preferably selected from the group consisting of: Fe, Mn, Ga, P, Mo, Re, Co and Cu, or a salt thereof. Methods for treatment, catalysis, and detection using the compounds are also described.

公开(公告)号：WO2022129116A1

公开(公告)日：2022-06-23

申请号：PCT/EP2021/085803

申请日：2021-12-15

Applicant: MERCK PATENT GMBH

Inventor： STOESSEL, Philipp

IPC: C07D487/06 ,  C07D487/22 ,  C07D471/16 ,  C07D491/16 ,  C07D491/22 ,  C07D498/22 ,  C07F7/02 ,  C07F7/10 ,  C07F15/00 ,  C09K11/06 ,  H01J1/63 ,  H01J29/08 ,  H01L29/08 ,  H01J35/24 ,  H01L51/00 ,  H01L51/50 ,  H01L51/56

Abstract: lndolo[3.2.1-jk]carbazole-6-carbonitril-Derivate der Formel (I) als blau fluoreszierende Emitter in organischen Elektrolumineszenzvorrichtungen, insbesondere OLEDs.

公开(公告)号：WO2022074014A1

公开(公告)日：2022-04-14

申请号：PCT/EP2021/077470

申请日：2021-10-05

Applicant: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG ,  FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Inventor： ALBRECHT, Volker ,  VON BRIESEN, Hagen ,  SCHEGLMANN, Dietrich ,  GITTER, Burkhard ,  WIEHE, Arno ,  WAGNER, Sylvia ,  GERMANN, Anja ,  STEEN, Dorika ,  WIELAND, Gerhard

IPC: C07D487/22 ,  A61K31/555 ,  A61P31/04 ,  A61P31/12

Abstract: Biologically active compounds are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for phototherapy, including photodynamic therapy, of viral or bacterial infections. As the compounds exhibit also toxicity against targets (bacteria, viruses) without light these biologically active compounds may also be used for the light- independent treatment of such diseases. Embodiments include porphyrins, chlorins, and dihydroxy chlorins as well as their zinc complexes. Also included are embodiments where these compounds are incorporated into liposomal formulations.